Cisplatin, Fluorouracil, and Pembrolizumab
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Cisplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 1 | Head and Neck Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 1 | Adenocarcinoma of the Gastroesophageal Junction | Cisplatin, Fluorouracil, Pembrolizumab |